Precipio Inc. reported revenue of $7.0 million for the second quarter of 2025, marking the company’s first profitable quarter amid a broader operational turnaround. The diagnostics provider attributed the performance to improved cost management and sustained demand for its testing services.
Revenue growth accelerated sequentially, reversing a multi-quarter trend of declining sales. The company did not disclose net income figures in its preliminary results, but executives highlighted that profitability was achieved through a combination of higher utilization rates and reduced overhead expenses.
Precipio’s management emphasized the role of strategic partnerships in stabilizing revenue streams, particularly in its core molecular diagnostics segment. The firm also noted progress in expanding its service offerings, which contributed to the quarter’s improved margins.
Analysts tracking the company’s turnaround cited the shift from loss-making operations to profitability as a key inflection point. Precipio’s shares, listed on the OTC Markets, have gained 12% in after-hours trading following the announcement.
The company plans to provide a full earnings report, including detailed financial statements and forward guidance, in the coming weeks.
